Go to homepage
Go to homepage
Your Cart
US$0.00

Clinical Peptides in Research

Clinical peptides play a vital role in immunotherapy, disease treatment, and regenerative medicine. JPT’s high-quality clinical peptides support groundbreaking research in autoimmune diseases, infectious diseases, and cancer immunotherapy. Below, you will find key studies referencing JPT’s clinical peptides in recent research.

References with Clinical Peptides

2022

2022

  • A small CEACAM5 peptide restores the protective function of CD8+ regulatory T cells in Crohn’s disease
    Dunkin et al., Gastroenterology (2022) - PMID: 35700774
  • Rapid single-cell identification of EpsteinBarr virus-specific T-cell receptors for cellular therapy
    Lammoglia Cobo et al., Cytotherapy (2022) - 35525797
  • Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL
    Lammoglia Cobo et al., PLoS Pathogens (2022) - PMID: 35452490
2021

2021

  • Designing Personalized Antigen-Specific Immunotherapies for Autoimmune Diseases—The Case for Using Ignored Target Cell Antigen Determinants
    Tian et al., Cells (2022)
  • Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy
    Basar et al., Cell Reports (2021)
  • Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant
    Lulla et al., Blood (2021)
  • Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine 2 Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled
    Pittisuttihum et al., MedRxiv (2021)
  • Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy
    Lak et al., MedRxiv (2021)
  • T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects
    Vasileiou et al., Journal of Clinical Oncology (2021) - PMID : 33507803
  • Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs
    Weingarten-Gabbay et al., Cell (2021) - PMID: 34171305
Archive

Archive

  • Preclinical Development and Clinical-Scale Manufacturing of HIV Gag-Specific, Lentivirus Modified CD4 T Cells for HIV Functional Cure
    Li et al., Molecular Therapy (2020)
  • Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections
    Vasileiou et al., Haematologica (2020) - PMID: 31004020
  • Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients
    Nelson et al., Blood Advances (2020)
  • The effects of β1 and β1+2 adrenergic receptor blockade on the exercise-induced mobilization and ex vivo expansion of virus-specific T cells: implications for cellular therapy and the anti-viral immune effects of exercise
    Kunz et al., Cell Stress and Chaperones (2020) - PMID: 32779001
  • HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform
    Patel et al., Molecular Therapy: Methods & Clinical Developement (2020)
  • Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in high-risk melanoma patients
    Pavlick et al., Cancer Immunology Research (2020) - PMID : 31699709
  • Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients
    Bhatt et al. Journal of Experimental Medicine (2020) - PMID: 32716518
  • An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection
    Brennick et al., Journal of Clinical Investigation (2020)
  • Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme
    Smith et al., Journal of Clinical Investigation (2020)
  • Peptide Pools For Target Antigen Identification, Immune Monitoring, and Cellular Therapy
    A.Castro et al., Cytotherapy (2020) - PMID: n.a.
  • “Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients
    Tzannou et al., Blood Advances (2019) - PMID : 31481503
  • T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy
    Keller et al., British Journal of Haematology (2019) - PMID: 31219185
  • A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo
    Vormehr et al., Oncoimmunology (2019)
  • Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant patients: A single-arm open-label phase I clinical trial
    Smith et al., Clinical Trial (2019) - PMID: 29982441
  • HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy
    Sung et al., Molecular Therapy (2018)
  • Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
    Ramos et al., Journal of Clinical Investigation (2017) - PMID: 28805662
  • Autologous Adoptive T-Cell Therapy for Recurrent or Drug-Resistant Cytomegalovirus Complications in Solid Organ Transplant Patients: A Single-Arm Open-Label Phase I Clinical Trial
    Smith et al., Infectious Diseases Society of America (2016) - PMID: 29982441
  • Human Parainfluenza Virus-3 Can be Targeted by Rapidly Ex Vivo Expanded T Lymphocytes
    McLaughlin et al., Cytotherapy (2016) - PMID: 27692559
  • Peptide‐Stimulated Expansion of Virus‐Specific T Cells for Preventative Treatment After Allogeneic Stem Cell Transplantation
    Gary et al., AppNote (2015) - PMID: n.a.
  • Broadly-Specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy
    Lam et al., Molecular Therapy (2015) - PMID: 25366030
  • Expanded Cytotoxic T-Cell Lymphocytes Target the Latent HIV Reservoir
    Sung et al., Journal of Infectious Diseases (2015) - PMID: 25589335
  • Ex vivo Expansion of Human T cells for Adoptive Immunotherapy Using the Novel Xeno-free CTS Immune Cell Serum Replacement
    Smith et al., Clinical & Translational Immunology (2015) - PMID: 25671129
  • PepMixes to Generate Multiviral CTLS with Broad Specificity
    Leen et al., US Patent 20,150,010,519 (2015)
  • Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma
    Krishnadas et al., Pediatrics. (2013) - PMID: 23266925
  • QIMR Berghofer Medical Research Institute Selects JPT’s GxP PepMix™ Peptide Pool Technology to Support its Phase I/II Clinical Trials of Adoptive Immunotherapy for Human Cytomegalovirus-associated Diseases
    Press Release (2014)
  • Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections After HSCT
    Papadopoulou et al., Sci Transl Med. (2014) - PMID: 24964991
  • Immunotherapeutic Strategies to Prevent and Treat Human Herpesvirus 6 Reactivation after Allogeneic Stem Cell Transplantation
    Gerdemann et al. (2013) - PMID: 23152545
  • Rapidly Generated Multivirus-specific Cytotoxic T lymphocytes for the Prophylaxis and Treatment of Viral Infections
    Gerdemann et al., Mol Ther. (2012) - PMID: 22801446
  • LMP-Specific T-Cells for Patients With Relapsed EBV-Positive Lymphoma (ALCI)
    Bollard et al. (2012) - PMID: n.a
  • Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma
    Gerdemann et al., Molecular Therapy (2011) - PMID: 21915103
  • Cytotoxic T Lymphocyte Therapy with Donor T Cells Prevents and Treats Adenovirus and Epstein-Barr Virus Infections after Haploidentical and Matched Unrelated Stem Cell Transplantation
    Leen et al., Blood (2009) - PMID: 19700662
Loading...
Clinical Peptides

Check our list of products, click and go.

Get a quote